人工智能驱动的精准医疗技术公司Tempus AI（纳斯达克代码：TEM）今日盘中股价大涨5.21%，引起市场广泛关注。
消息面上，Tempus AI宣布其新开发的Tempus ECG-Low EF软件已获得美国食品药品监督管理局（FDA）的510(k)许可。这是该公司心血管产品系列中第二款获得FDA许可的ECG-AI设备，标志着Tempus AI在心脏健康监测领域取得重大突破，进一步巩固了公司在精准医疗市场的地位。
Tempus ECG-Low EF是一款由人工智能驱动的软件，旨在识别可能存在低左心室射血分数（LVEF）的患者。该软件通过分析静息、非移动的12导联心电图记录，检测与40%或更低LVEF相关的迹象。这一创新技术将为临床医生提供强大工具，帮助及早识别有严重心血管疾病风险的患者，从而改善患者护理和治疗效果。Tempus AI的这一突破性进展不仅展示了公司在AI医疗领域的创新能力，也为投资者带来了积极信号，反映在今日的股价表现上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.